EUSA Pharma raises $175mm to launch and fund purchase
Executive Summary
Specialty pharmaceuticals start-up EUSA Pharma Inc. raised $175mm in its second round of venture financing. Essex Woodlands and 3i led the round and were joined by Goldman Sachs, Advent Venture Partners, NeoMed, and NovaQuest. The company will use the proceeds to acquire French drug company OPi, which develops treatments for blood cancers and other critical diseases, and to officially commence operations. EUSA was originally founded in 2006 and has raised $19mm through prior investments.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Transdermal
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice